BANK VONTOBEL/CALL/NOVO NORDISK ADR B/130/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 01:50:32 2024-05-31 pm EDT | ||
| 1.06 EUR | -.--% |
|
| 1 month | +4.95% | ||
| 3 months | +49.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.06 | -.--% |
| 24-05-30 | 1.06 | +3.92% |
| 24-05-29 | 1.02 | -5.56% |
| 24-05-28 | 1.08 | -.--% |
| 24-05-27 | 1.08 | -13.60% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:50 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM31AA |
| ISIN | DE000VM31AA1 |
| Date issued | 2023-10-16 |
| Strike | 130 $ |
| Maturity | 2024-09-20 (110 Days) |
| Parity | 10 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.68 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.01 € |
| Spread % | 0.86% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
